公开(公告)号：US20100125058A1

公开(公告)日：2010-05-20

申请号：US12614485

申请日：2009-11-09

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  Hong Ying Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  Hong Ying Yun ,  Zhenshan Zhang

IPC分类号： A61K31/397 ,  A61K31/44 ,  C07D211/72 ,  A61K31/19 ,  C07C315/00 ,  C07D241/04 ,  A61K31/497 ,  C07D205/00

CPC分类号： C07D213/71 ,  C07C255/54 ,  C07C311/29 ,  C07C317/22 ,  C07C317/36 ,  C07C317/44 ,  C07C317/46 ,  C07C323/65 ,  C07C2601/02 ,  C07C2601/08 ,  C07D211/38 ,  C07D295/26 ,  C07D491/10

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中W，X，Y和R 1 -R 7在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症，例如哮喘。

公开(公告)号：US08642629B2

公开(公告)日：2014-02-04

申请号：US12614485

申请日：2009-11-09

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Eric Mertz ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/44 ,  C07D213/02

CPC分类号： C07D213/71 ,  C07C255/54 ,  C07C311/29 ,  C07C317/22 ,  C07C317/36 ,  C07C317/44 ,  C07C317/46 ,  C07C323/65 ,  C07C2601/02 ,  C07C2601/08 ,  C07D211/38 ,  C07D295/26 ,  C07D491/10

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein W, X, Y, and R1-R7 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中W，X，Y和R 1 -R 7在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症，例如哮喘。

公开(公告)号：US08138208B2

公开(公告)日：2012-03-20

申请号：US12497807

申请日：2009-07-06

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/4439 ,  A61K31/416 ,  C07D231/54 ,  C07D401/02

CPC分类号： C07D231/56 ,  C07D401/12 ,  C07D413/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，W，X，R 1 -R 5和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US08420675B2

公开(公告)日：2013-04-16

申请号：US13342150

申请日：2012-01-02

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/416 ,  A61K31/4439 ,  A61K31/4245 ,  C07D413/12 ,  C07D401/12 ,  C07D231/54

CPC分类号： C07D231/56 ,  C07D401/12 ,  C07D413/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1—R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，W，X，R 1 -R 5和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20120101131A1

公开(公告)日：2012-04-26

申请号：US13342150

申请日：2012-01-02

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/416 ,  C07D413/12 ,  A61P11/06 ,  C07D401/12 ,  A61K31/4439 ,  C07D231/54 ,  A61K31/4245

CPC分类号： C07D231/56 ,  C07D401/12 ,  C07D413/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，W，X，R 1 -R 5和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US08163781B2

公开(公告)日：2012-04-24

申请号：US12540804

申请日：2009-08-13

申请人： Jean-Baptiste Blanc ,  Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Robert Alan Goodnow, Jr. ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Jean-Baptiste Blanc ,  Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Robert Alan Goodnow, Jr. ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： C07D213/62 ,  A61K31/4412

CPC分类号： C07D213/71 ,  C07C311/20 ,  C07C311/29 ,  C07C317/14 ,  C07C323/67 ,  C07C2602/10 ,  C07D213/34 ,  C07D409/04

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中R1-R5，A，B，Q，W和X在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20100041714A1

公开(公告)日：2010-02-18

申请号：US12540804

申请日：2009-08-13

申请人： Jean-Baptiste Blanc ,  Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Robert Alan Goodnow, JR. ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Jean-Baptiste Blanc ,  Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Robert Alan Goodnow, JR. ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/4412 ,  C07C317/14 ,  C07D213/62 ,  A61K31/196 ,  A61P37/08

CPC分类号： C07D213/71 ,  C07C311/20 ,  C07C311/29 ,  C07C317/14 ,  C07C323/67 ,  C07C2602/10 ,  C07D213/34 ,  C07D409/04

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中R1-R5，A，B，Q，W和X在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20120095053A1

公开(公告)日：2012-04-19

申请号：US13324650

申请日：2011-12-13

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC分类号： A61K31/4439 ,  C07D401/12 ,  A61P11/06 ,  C07D405/14

CPC分类号： C07D231/56 ,  C07D401/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，R 1 -R 3和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20100016368A1

公开(公告)日：2010-01-21

申请号：US12497786

申请日：2009-07-06

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC分类号： A61K31/416 ,  C07D231/56 ,  C07D401/12 ,  A61K31/4439

CPC分类号： C07D231/56 ,  C07D401/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，R 1 -R 3和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US08124641B2

公开(公告)日：2012-02-28

申请号：US12497786

申请日：2009-07-06

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC分类号： A61K31/4439 ,  C07D401/12

CPC分类号： C07D231/56 ,  C07D401/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，R 1 -R 3和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。